Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

  • April 2021 •
  • 201 pages •
  • Report ID: 5443604 •
  • Format: PDF
Abstract:
- Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $23.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$23.8 Billion by 2027, growing at aCAGR of 5% over the period 2020-2027. Stimulant, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Stimulant segment is readjusted to a revised 6.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $5 Billion, While China is Forecast to Grow at 4.7% CAGR
- The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

- Select Competitors (Total 27 Featured) -
  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.